Kern Subbasin Groundwater Sustainability Agencies Urge State to Consider Updated PlanBusiness Wire • 08/30/24
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart MusclesBenzinga • 08/30/24
Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags ExpectationsInvestors Business Daily • 08/30/24
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology CongressBusiness Wire • 08/30/24
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid CompetitionZacks Investment Research • 08/23/24
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024Business Wire • 08/07/24
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period ActivityBusiness Wire • 08/01/24
Seeking Clues to Alnylam (ALNY) Q2 Earnings? A Peek Into Wall Street Projections for Key MetricsZacks Investment Research • 07/30/24
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial ResultsBusiness Wire • 07/18/24
35% Surge Just the Beginning? Alnylam's Stock Poised for Massive Gains on Heart Drug Success.InvestorPlace • 07/11/24
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares SurgeBenzinga • 06/24/24